ArticleJournal of clinical and translational hepatology2023
Breath Biopsy
Article in Journal of clinical and translational hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- Exploring Components, Sensors, and Techniques for Cancer Detection via eNose Technology: A Systematic Review.Sensors (Basel, Switzerland) · 2024Pooled it
- A comprehensive meta-analysis and systematic review of breath analysis in detection of COVID-19 through Volatile organic compounds.Diagnostic microbiology and infectious disease · 2024Pooled it
- [Advances in the application of exhaled breath analysis technology in the detection and diagnosis of liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Breath-Based Diagnostics in Liver Diseases: Dynamic Assessment of Hepatic Metabolic Reserve and Liver Fibrosis.Gastro hep advances · 2026Review
- The potential of distributed diagnostics for the early detection of Parkinson's disease.Journal of Parkinson's disease · 2025Review
- Optimized breath analysis: customized analytical methods and enhanced workflow for broader detection of VOCs.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Non-Invasive Biomarkers and Breath Tests for Diagnosis and Monitoring of Chronic Liver Diseases.Diagnostics (Basel, Switzerland) · 2024Review
- High-quality identification of volatile organic compounds (VOCs) originating from breath.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Progress and challenges of developing volatile metabolites from exhaled breath as a biomarker platform.Metabolomics : Official journal of the Metabolomic Society · 2024Review
- Biomarkers for Early Cancer Detection: A Landscape View of Recent Advancements, Spotlighting Pancreatic and Liver Cancers.ACS pharmacology & translational science · 2024Review
- Predicting Chronological Age via the Skin Volatile Profile.Journal of the American Society for Mass Spectrometry · 2024Article
- Volatile organic compounds for the detection of hepatocellular carcinoma-A scoping review.iLIVER · 2024Review
- A matrix-centered view of mass spectrometry platform innovation for volatilome research.Frontiers in molecular biosciences · 2024Review
- Exogenous Volatile Organic Compound (EVOCBiomedicines · 2023Article
- [Functional recompensation during decompensated-stage cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 2 countries.
Funding
Abstract
Background and Aims: The prevalence of chronic liver disease in adults exceeds 30% in some countries and there is significant interest in developing tests and treatments to help control disease progression and reduce healthcare burden. Breath is a rich sampling matrix that offers non-invasive solutions suitable for early-stage detection and disease monitoring. Having previously investigated targeted analysis of a single biomarker, here we investigated a multiparametric approach to breath testing that would provide more robust and reliable results for clinical use. Methods: To identify candidate biomarkers we compared 46 breath samples from cirrhosis patients and 42 from controls. Collection and analysis used Breath Biopsy OMNI™, maximizing signal and contrast to background to provide high confidence biomarker detection based upon gas chromatography mass spectrometry (GC-MS). Blank samples were also analyzed to provide detailed information on background volatile organic compounds (VOCs) levels. Results: A set of 29 breath VOCs differed significantly between cirrhosis and controls. A classification model based on these VOCs had an area under the curve (AUC) of 0.95±0.04 in cross-validated test sets. The seven best performing VOCs were sufficient to maximize classification performance. A subset of 11 VOCs was correlated with blood metrics of liver function (bilirubin, albumin, prothrombin time) and separated patients by cirrhosis severity using principal component analysis. Conclusions: A set of seven VOCs consisting of previously reported and novel candidates show promise as a panel for liver disease detection and monitoring, showing correlation to disease severity and serum biomarkers at late stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.